Literature DB >> 30903735

Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity.

Chiara Cantarelli1, Andrea Angeletti2, Paolo Cravedi1.   

Abstract

Erythropoietin (EPO) is a glycoprotein produced mainly by the adult kidney in response to hypoxia and is the crucial regulator of red blood cell production. EPO receptors (EPORs), however, are not confined to erythroid cells, but are expressed by many organs including the heart, brain, retina, pancreas, and kidney, where they mediate EPO-induced, erythropoiesis-independent, tissue-protective effects. Some of these tissues also produce and locally release small amounts of EPO in response to organ injury as a mechanism of self-repair. Growing evidence shows that EPO possesses also important immune-modulating effects. Monocytes can produce EPO, and autocrine EPO/EPOR signaling in these cells is crucial in maintaining immunologic self-tolerance. New data in mice and humans also indicate that EPO has a direct inhibitory effect on effector/memory T cells, while it promotes formation of regulatory T cells. This review examines the nonerythropoietic effects of EPO, with a special emphasis on its modulating activity on innate immune cells and T cells and on how it affects transplant outcomes.
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  T cell biology; erythropoietin; immunobiology; immunosuppression/immune modulation; kidney transplantation/nephrology; translational research/science

Year:  2019        PMID: 30903735      PMCID: PMC6711804          DOI: 10.1111/ajt.15369

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  60 in total

Review 1.  Regulation of the erythropoietin gene.

Authors:  B L Ebert; H F Bunn
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

Review 2.  Why is erythropoietin made in the kidney? The kidney functions as a critmeter.

Authors:  S Donnelly
Journal:  Am J Kidney Dis       Date:  2001-08       Impact factor: 8.860

3.  Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling.

Authors:  Laura Calvillo; Roberto Latini; Jan Kajstura; Annarosa Leri; Piero Anversa; Pietro Ghezzi; Monica Salio; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-27       Impact factor: 11.205

4.  The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin.

Authors:  Xiaoyang Wang; Changlian Zhu; Xinhua Wang; Jens Gammeltoft Gerwien; Andre Schrattenholz; Mats Sandberg; Marcel Leist; Klas Blomgren
Journal:  J Neurochem       Date:  2004-11       Impact factor: 5.372

5.  Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse.

Authors:  Salvatore Cuzzocrea; Emanuela Mazzon; Rosanna di Paola; Tiziana Genovese; Nimesh S A Patel; Domenico Britti; Massimo de Majo; Achille P Caputi; Christoph Thiemermann
Journal:  Arthritis Rheum       Date:  2005-03

6.  Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications.

Authors:  Zongzhong Tong; Zhenglin Yang; Shrena Patel; Haoyu Chen; Daniel Gibbs; Xian Yang; Vincent S Hau; Yuuki Kaminoh; Jennifer Harmon; Erik Pearson; Jeanette Buehler; Yuhong Chen; Baifeng Yu; Nicholas H Tinkham; Norman A Zabriskie; Jiexi Zeng; Ling Luo; Jennifer K Sun; Manvi Prakash; Rola N Hamam; Stephen Tonna; Ryan Constantine; Cecinio C Ronquillo; SriniVas Sadda; Robert L Avery; John M Brand; Nyall London; Alfred L Anduze; George L King; Paul S Bernstein; Scott Watkins; Lynn B Jorde; Dean Y Li; Lloyd Paul Aiello; Martin R Pollak; Kang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

7.  Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.

Authors:  Michael Brines; Nimesh S A Patel; Pia Villa; Courtenay Brines; Tiziana Mennini; Massimiliano De Paola; Zubeyde Erbayraktar; Serhat Erbayraktar; Bruno Sepodes; Christoph Thiemermann; Pietro Ghezzi; Michael Yamin; Carla C Hand; Qiao-wen Xie; Thomas Coleman; Anthony Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-01       Impact factor: 11.205

8.  Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model.

Authors:  Harumi Kitamura; Yoshitaka Isaka; Yoshitsugu Takabatake; Ryoichi Imamura; Chigure Suzuki; Shiro Takahara; Enyu Imai
Journal:  Nephrol Dial Transplant       Date:  2008-01-14       Impact factor: 5.992

9.  Erythropoietin reduces the development of experimental inflammatory bowel disease.

Authors:  Salvatore Cuzzocrea; Emanuela Mazzon; Rosanna Di Paola; Nimesh S A Patel; Tiziana Genovese; Carmelo Muià; Angelina De Sarro; Christoph Thiemermann
Journal:  J Pharmacol Exp Ther       Date:  2004-08-09       Impact factor: 4.030

10.  Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE.

Authors:  RuiRong Yuan; Yasuhiro Maeda; Weiping Li; Wei Lu; Stuart Cook; Peter Dowling
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

View more
  21 in total

Review 1.  Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms.

Authors:  Tetsuji Miura; Tatsuya Sato; Toshiyuki Yano; Akira Takaguri; Takayuki Miki; Noritsugu Tohse; Keitaro Nishizawa
Journal:  Cardiovasc Drugs Ther       Date:  2022-02-12       Impact factor: 3.727

Review 2.  Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?

Authors:  Sidar Copur; Abdullah Yildiz; Carlo Basile; Katherine R Tuttle; Mehmet Kanbay
Journal:  J Nephrol       Date:  2022-08-13       Impact factor: 4.393

3.  Effect of Erythropoietin on Mononuclear Cells of the Bone Marrow and Spleen.

Authors:  A P Lykov; M A Surovtseva; N A Bondarenko; I I Kim; Ya Sh Schwartz; O V Poveshchenko
Journal:  Bull Exp Biol Med       Date:  2022-10-10       Impact factor: 0.737

Review 4.  Erythropoietin in Optic Neuropathies: Current Future Strategies for Optic Nerve Protection and Repair.

Authors:  Yi-Fen Lai; Ting-Yi Lin; Pin-Kuan Ho; Yi-Hao Chen; Yu-Chuan Huang; Da-Wen Lu
Journal:  Int J Mol Sci       Date:  2022-06-27       Impact factor: 6.208

5.  Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines.

Authors:  Richard M Logan; Abdul Rahman Al-Azri; Paolo Bossi; Andrea M Stringer; Jamie K Joy; Yoshihiko Soga; Vinisha Ranna; Anusha Vaddi; Judith E Raber-Durlacher; Rajesh V Lalla; Karis Kin Fong Cheng; Sharon Elad
Journal:  Support Care Cancer       Date:  2020-02-21       Impact factor: 3.603

6.  The Impact of Erythropoietin on Short- and Long-Term Kidney-Related Outcomes in Neonates of Extremely Low Gestational Age. Results of a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial.

Authors:  David J Askenazi; Patrick J Heagerty; Robert H Schmicker; Patrick Brophy; Sandra E Juul; Stuart L Goldstein; Sangeeta Hingorani
Journal:  J Pediatr       Date:  2021-01-20       Impact factor: 4.406

7.  Erythropoietin in bone homeostasis-Implications for efficacious anemia therapy.

Authors:  Katrina M Lappin; Ken I Mills; Terence R Lappin
Journal:  Stem Cells Transl Med       Date:  2021-01-21       Impact factor: 6.940

Review 8.  Clinical Application of Cytokines in Cancer Immunotherapy.

Authors:  Yi Qiu; Mengxi Su; Leyi Liu; Yiqi Tang; Yuan Pan; Jianbo Sun
Journal:  Drug Des Devel Ther       Date:  2021-05-27       Impact factor: 4.162

Review 9.  STAT5 as a Key Protein of Erythropoietin Signalization.

Authors:  Zuzana Tóthová; Jana Tomc; Nataša Debeljak; Peter Solár
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

10.  Erythropoietin Reduces Auto- and Alloantibodies by Inhibiting T Follicular Helper Cell Differentiation.

Authors:  Chiara Guglielmo; Sofia Bin; Chiara Cantarelli; Susan Hartzell; Andrea Angeletti; Chiara Donadei; Arun Cumpelik; Lisa Anderson; Evan Cody; Peter T Sage; Gaetano La Manna; Enrico Fiaccadori; Peter S Heeger; Paolo Cravedi
Journal:  J Am Soc Nephrol       Date:  2021-07-14       Impact factor: 14.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.